ArticleJournal for immunotherapy of cancer2021

First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas.

Sarina A Piha-Paul et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.